Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial
Thank you for registering! Take a moment to confirm your subscription to Insider Trades Newsletter so that you can access MarketBeat's tools, reports, and news. Please click the "Send Confirmation Email" button and we'll send you an email with confirmation instructions.
OTCMKTS:HLOSF

Healios K.K. (HLOSF) Stock Price, News & Analysis

0.97
-0.03 (-2.86%)
(As of 05/17/2024 08:55 PM ET)
Today's Range
0.97
0.97
50-Day Range
0.94
0.99
52-Week Range
0.94
1.31
Volume
100 shs
Average Volume
1,100 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
HLOSF stock logo

About Healios K.K. Stock (OTCMKTS:HLOSF)

Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051 for treatment of ischemic stroke and acute respiratory distress syndrome; HLCN061 for treating solid tumors; HLCR011 for the treatment of retinal pigment epithelium tear and age-related macular degeneration; and HLCL041 for liver disease. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Tokyo, Japan.

HLOSF Stock Price History

HLOSF Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:HLOSF
CIK
N/A
Fax
N/A
Employees
64
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Dr. Tadahisa S. Kagimoto M.D. (Age 48)
    Chairman & CEO
  • Mr. Richard P. Kincaid (Age 48)
    CFO, Executive Officer & Internal Director
  • Mr. Masanori Sawada M.D. (Age 43)
    MBA, Ph.D., Executive VP, Chief Medical Officer and In Charge of Development & Human Resources & General Affairs
  • Mr. Kouichi Tamura Ph.D. (Age 68)
    Exec. Off., Chief Scientific Off., In Charge of Res. & Manufacturing and Head of Kobe Res. Institute
  • Mr. Yoshinari Matsuda (Age 46)
    Managing Director

HLOSF Stock Analysis - Frequently Asked Questions

How have HLOSF shares performed in 2024?

Healios K.K.'s stock was trading at 1.59 on January 1st, 2024. Since then, HLOSF stock has decreased by 39.1% and is now trading at 0.97.
View the best growth stocks for 2024 here
.

Are investors shorting Healios K.K.?

Healios K.K. saw a decrease in short interest in the month of April. As of April 15th, there was short interest totaling 365,900 shares, a decrease of 6.4% from the March 31st total of 391,100 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is presently ∞ days.
View Healios K.K.'s Short Interest
.

How do I buy shares of Healios K.K.?

Shares of HLOSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:HLOSF) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners